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Letter to the Editor
It has become clear that there are distinct interrelationships between recurring genetic mutations in acute myeloid leukemia (AML). Whereas certain mutations frequently coexist in AML, others are mutually exclusive. Mutations in NPM1 and RUNX1, two of the most commonly mutated genes in AML, are almost entirely mutually exclusive. In six recent studies that evaluated the frequency of both NPM1 and RUNX1 mutations in AML, [1] [2] [3] [4] [5] [6] these two mutations coexisted in just 0.6% (13/2348) of the cases. In the two studies conducted by our group, 1,4 which included large cohorts of patients with primary AML and a normal karyotype (n=392) 4 and patients with sole trisomy 8 (n=80), 1 NPM1
and RUNX1 mutations coexisted in 0.8% (4/472) of the patients. The goal of the study reported herein was to more closely examine these few AML patients carrying both mutations in order to better understand the relationship between NPM1 and RUNX1 mutations in AML.
Clinical and molecular characteristics of the four patients with coexisting RUNX1 and NPM1 mutations are provided in Table 1 To determine whether RUNX1 and NPM1 mutations were somatically acquired in AML patients harboring both mutations, pretreatment germline material was screened in those RUNX1-mutated/NPM1-mutated patients for whom buccal cells were available (UPN 1-
. Surprisingly, in all three cases, the same RUNX1 mutation identified in leukemic blasts was also present in the germline ( Figure 1b ). In contrast, NPM1 mutations were not detected in the germline (Figure 1c ), confirming that germline material was not contaminated with leukemic cells. To determine the specificity of this finding to NPM1-mutated cases, we next tested the frequency of germline RUNX1 mutations in NPM1-wildtype patients known to have RUNX1 mutations in their leukemic blasts. Of the RUNX1-mutated/NPM1-wildtype patients with buccal cells available (n=56), none harbored germline RUNX1 mutations (P<0.001). Thus, in our cohort, AML patients with coexisting RUNX1 and NPM1 mutations were not found to acquire both of these mutations somatically; rather, our data suggest that RUNX1 mutations pre-existed and NPM1 mutations were a later, acquired event.
We considered the possibility that these germline RUNX1 mutations may have been however, since the recorded family histories included information on first-degree relatives only and RUNX1 mutation-associated syndromic disease is variably expressed 11 , this analysis was insufficient for formal evaluation of familial phenotype.
To attempt to address the disease potential of the RUNX1 mutations discovered here, we subjected them to MutationTaster analysis, which is a free, web-based application for the evaluation of disease-causing potential of DNA sequence variations. 12 This analysis predicted that c.952T>G and c.1098_1103delCGGCAT were likely to be harmless polymorphisms; in contrast, c.620G>A and c.155T>A were predicted to be diseasepredisposing. Supporting the likelihood that c.620G>A plays a causal role in AML pathogenesis is the fact that it was somatically acquired in another patient within our cytogenetically normal AML cohort. 4 Despite these predictions, the extent to which the germline RUNX1 mutations discovered here contributed to the pathogenesis of AML remains unclear.
Although several previous studies have highlighted the near mutual exclusivity of RUNX1 and NPM1 mutations, [1] [2] [3] [4] [5] [6] to our knowledge, no prior study has closely examined the rare AML cases harboring both mutations. We found that the RUNX1 mutations in these cases are structurally unusual relative to the majority of those found in AML; namely, they are in-frame, located outside the RD, and present in the germline. The functional significance of these types of RUNX1 mutations has not been established 13 and future studies should be aimed at determining whether they are innocent polymorphisms or disease-predisposing alleles. The complete exclusivity between RUNX1 mutations known to be disease-predisposing and NPM1 mutations in our AML cohort suggests that they may have redundant roles in promoting leukemogenesis. This role may be in causing expansion of the myeloid precursor cell compartment, as recently demonstrated in mouse models expressing either RUNX1 14 or NPM1 15 mutations in primitive hematopoietic progenitor cells.
In summary, our work suggests that NPM1 mutations do not coexist with "classical"
RUNX1 mutations (i.e., those RUNX1 mutations known to be disease-predisposing) in primary AML. In rare patients harboring both NPM1 and RUNX1 mutations, NPM1 mutations seem to be acquired in the context of pre-existing RUNX1 mutations of unclear functional significance. Thus, our work adds to the growing body of knowledge defining key mutational interrelationships underlying the pathogenesis of AML. 
